Your browser doesn't support javascript.
loading
Transcriptomic and behavioural characterisation of a mouse model of burn pain identify the cholecystokinin 2 receptor as an analgesic target.
Yin, Kathleen; Deuis, Jennifer R; Lewis, Richard J; Vetter, Irina.
Afiliação
  • Yin K; Centre for Pain Research, Institute for Molecular Bioscience, University of Queensland, Queensland, Australia.
  • Deuis JR; Centre for Pain Research, Institute for Molecular Bioscience, University of Queensland, Queensland, Australia.
  • Lewis RJ; Centre for Pain Research, Institute for Molecular Bioscience, University of Queensland, Queensland, Australia.
  • Vetter I; Centre for Pain Research, Institute for Molecular Bioscience, University of Queensland, Queensland, Australia Pharmacy Australia Centre of Excellence, University of Queensland, Queensland, Australia i.vetter@uq.edu.au.
Mol Pain ; 122016.
Article em En | MEDLINE | ID: mdl-27573516
ABSTRACT
Burn injury is a cause of significant mortality and morbidity worldwide and is frequently associated with severe and long-lasting pain that remains difficult to manage throughout recovery. We characterised a mouse model of burn-induced pain using pharmacological and transcriptomic approaches. Mechanical allodynia elicited by burn injury was partially reversed by meloxicam (5 mg/kg), gabapentin (100 mg/kg) and oxycodone (3 and 10 mg/kg), while thermal allodynia and gait abnormalities were only significantly improved by amitriptyline (3 mg/kg) and oxycodone (10 mg/kg). The need for relatively high opioid doses to elicit analgesia suggested a degree of opioid resistance, similar to that shown clinically in burn patients. We thus assessed the gene expression changes in dorsal root ganglion neurons and pathophysiological mechanisms underpinning burn injury-induced pain using a transcriptomic approach. Burn injury was associated with significantly increased expression of genes associated with axon guidance, neuropeptide signalling, behavioural defence response and extracellular signalling, confirming a mixed neuropathic and inflammatory aetiology. Notably, among the pain-related genes that were upregulated post-injury was the cholecystokinin 2 receptor (Cckbr), a G protein-coupled receptor known as a pain target involved in reducing opioid effectiveness. Indeed, the clinically used cholecystokinin receptor antagonist proglumide (30 mg/kg) was effective at reversing mechanical allodynia, with additional analgesia evident in combination with low-dose oxycodone (1 mg/kg), including significant reversal of thermal allodynia. These findings highlight the complex pathophysiological mechanisms underpinning burn injury-induced pain and suggest that cholecystokinin-2 receptor antagonists may be useful clinically as adjuvants to decrease opioid requirements and improve analgesic management.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Dor / Regulação da Expressão Gênica / Transtornos Neurológicos da Marcha / Receptor de Colecistocinina B / Transcriptoma / Hiperalgesia Tipo de estudo: Guideline / Prognostic_studies Idioma: En Revista: Mol Pain Assunto da revista: BIOLOGIA MOLECULAR / NEUROLOGIA / PSICOFISIOLOGIA Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Austrália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Dor / Regulação da Expressão Gênica / Transtornos Neurológicos da Marcha / Receptor de Colecistocinina B / Transcriptoma / Hiperalgesia Tipo de estudo: Guideline / Prognostic_studies Idioma: En Revista: Mol Pain Assunto da revista: BIOLOGIA MOLECULAR / NEUROLOGIA / PSICOFISIOLOGIA Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Austrália
...